Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (555)	4/25/2000 3:16:00 PM
From: biowa	Respond to of 666

Peter, True, except that ROW did not include Japan under the original agreement. Thus, for this product, this is essentially Europe and Canada. Under the original agreement, SB apparently paid for all development costs and was responsible for all filings ex-US. This may not seem like a worthwhile expense/effort without Europe. As you mention, SB had the option in the original agreement to terminate it on a country-by-country basis "based on a reasonable determination by SB that the patent, medical/scientific, technical, regulatory or commercial profile of [Bexxar] does not justify continued development or commercialization of [Bexxar] in such country." In other words, if SB wanted out they could've done so without losing the US part of the deal, so IMO there is something else going on. Personally, I suspect that its somewhere between your most optimistic scenario (that SKB just doesn't have an oncology presence ex-US) and your median scenario (with manufacturing cost as the deterrent). biowa